MindMed Activist Investor Moves To Take Control Of Board
MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its proposed set of directors after
Read more
Mind Medicine
Proxy Fight Looms For MindMed Vs. Co-Founder
Mind Medicine’s (NASDAQ: MNMD) filed its preliminary proxy materials on Tuesday with the U.S. Securities and Exchange Commission (SEC) for its
Read more
MindMed Expects Results For Anxiety, ADHD Trials By Late 2023
It seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as the firm gave updates on
Read more
Activist Investor Calls For MindMed CEO’s Termination Due To Alleged Fraudulent Acts
FCM MM Holdings, one of Mind Medicine’s (NEO: MMED) shareholders with a 6.1% stake, has formally filed a complaint with
Read more
Mindmed: Canaccord Calls Financing “Puzzling And Unusual”
This past week Mind Medicine Inc. (NEO: MMED) announced that they would be doing a public offering of 7,058,823 units
Read more
Mind Medicine Prices $30 Million Offering At 30% Discount To Market
Mind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this morning, pricing yet another financing
Read more
MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the first patient has been dosed
Read more
MindMed Sees Positive Results For Its LSD Treatment For Anxiety Disorders Published In Peer-Reviewed Journal
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday that the previously released positive topline data
Read more
Mindmed Completes 15-To-1 Reverse Split To Maintain Nasdaq Compliance
Mind Medicine (NEO: MMED) might be slightly more volatile over the next few sessions. The psychedelic firm late on Friday
Read more
Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant
Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to
Read more